The journey is ongoing: with each new study and each patient success story, the legacy of GLP-1 drugs solidifies
That means using a combination of the following therapies: Dietary intervention Probiotics Prescription and/or Herbal Antibiotics Targeted nutritional supplementation The use of fermented food products Proper use of prebiotics to rebuild the GI flora Intermittent fasting to help reduce inflammation and decrease bacterial load Its also important to remember that unless you treat the underlying cause of your SIBO it is VERY likely to come back despite the intervention above
Focus on getting 20-30g protein per meal from plant sources
Satisfied Customers Very professional and friendly office with an abundance of knowledge and experience which has helped me target those areas of wellness to allow my days to be more at peak performance and mental clarity
SMC Chair Dr Rob Peel said: "Semaglutide will provide a useful treatment option to help reduce major cardiovascular events in patients who are overweight and have cardiovascular disease." Following the announcement, Sebnem Avsar Tuna, General Manager Novo Nordisk UK, said: "We are delighted that the SMC has recognised the value semaglutide can bring to the people in Scotland who are living with established cardiovascular disease and overweight or obesity, where the threat of a secondary event is a constant reality
It is a non-peptide, small-molecule GLP-1 receptor agonist
